Jake Chanin
Cardiovascular Disease · Denver, CONPI 1336460872
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Abbott at 30.1% of the total. Reporting peaked in 2024 at $34,139 and has fallen 78.2% since, to $7,433 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 801 payments — averaging $102.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$25K
- Medtronic$19K
- Edwards Lifesciences$14K
- Abiomed$12K
- Boston Scientific$7K
- Philips North America LLC$968
- plus $4K from 24 others
Across 75 payments — averaging $6717.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$350K
- Abbott$154K
What the payments were for
- Consulting fees$770%
- Speaking & faculty fees$8,81311%
- Travel & lodging$31,60238%
- Food & beverage$41,93151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 230 | $24,844 |
| Medtronic(2 entities) | 70 | $18,915 |
| Edwards Lifesciences | 171 | $14,429 |
| Abiomed | 115 | $11,726 |
| Boston Scientific | 105 | $7,307 |
| Philips North America LLC | 29 | $968 |
| Medical Device Business Services, Inc. | 7 | $887 |
| Shockwave Medical, Inc | 14 | $759 |
| Penumbra, Inc. | 5 | $556 |
| Livanova USA, Inc. | 6 | $345 |
| W. L. Gore & Associates, Inc. | 5 | $336 |
| Inari Medical, Inc. | 3 | $306 |
| Heartflow, Inc. | 8 | $185 |
| Terumo Medical Corporation | 2 | $136 |
| Cardiva Medical, Inc. | 6 | $116 |
| Cardiovascular Systems Inc. | 2 | $85 |
| Pfizer | 3 | $84 |
| Johnson & Johnson | 3 | $74 |
| Amgen | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Merck | 2 | $43 |
| Baylis Medical Company Inc | 2 | $34 |
| AstraZeneca | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Cordis US CORP. | 1 | $24 |
| Novartis | 1 | $23 |
| Corcym Inc | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$16,716
- MitraClip$10,403
- Impella$8,122
- CardioMEMS HF System$5,650
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,086
- AMPLATZER TALISMAN$2,416
- PASCAL$1,862
- Watchman$1,434
- WATCHMAN Access System$1,327
- GENERAL VASCULAR ACCESS$1,251
- EVOQUE$1,025
- Carto 3 System$825
- MitraClip System$727
- SAPIEN 3 Ultra RESILIA$585
- GENERAL - THERAPIES$547
- NAVITOR$447
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$417
- Indigo System$411
- Confida$361
- WATCHMAN FLX$292
How this compares
$82,422 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $101,357 |
| Repatha SureclickEvolocumab | 12 | $7,057 |
| Metoprolol Succinate | 92 | $959 |
| Carvedilol | 65 | $659 |
| Furosemide | 87 | $438 |
| Atorvastatin Calcium | 52 | $333 |
| Losartan Potassium | 49 | $286 |
| Metoprolol Tartrate | 18 | $220 |
| Amlodipine Besylate | 36 | $197 |
| ClopidogrelClopidogrel Bisulfate | 27 | $191 |
| Lisinopril | 44 | $183 |
| Potassium Chloride | 17 | $142 |
| Spironolactone | 22 | $99 |
| Rosuvastatin Calcium | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $101,35788 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Denver
- Andrew FreemanDenver$454K
- Sameer MehtaDenver$92K
- John RumsfeldDenver$24K
- Mori KrantzDenver$22K
- Fady IskanderDenver$16K
- Jose SanchezDenver$8K
- Sam RougasDenver$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- William SauerAurora$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.